Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung

Japanese Journal of Cancer Research

Volumn 92, Issue 3, 2001, Pages 285-292

  Xue, Q ^a   Sano, T ^a   Kashiwabara, K ^a   Oyama, T ^a   Nakajima, T ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Lung; P53 pathway; PRB pathway; Squamous cell carcinoma

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 2; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TECHNIQUE;

EID: 0035072838     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01093.x     Document Type: Article

References (53)

1. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
2. Molecular genetic correlates of p16, cdk4 and pRb immunohistochemistry in glioblastomas
3. Cancer cell cycles
4. p53 mutations in human cancers
5. The p53 pathway
6. DNA damage-induced activation of p53 by the check-point kinase Chk2
7. A cell cycle regulator potentially involved in genesis of many tumor types
8. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16 in archival human solid tumors: Correlation with retinoblastoma protein expression
9. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors
10. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias
11. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers
12. Inactivation of the CDKN2A/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
13. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
14. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
15. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
16. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
17. P14ARF links the tumour suppressors RB and p53
18. Arf, participates in a regulatory feedback loop with p53 and MDM2
19. Identification of frequent novel genetic alteration in small cell lung carcinoma
20. INK4a expression in resected non-small cell lung tumors
21. Alteration of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small cell lung carcinomas: Relationship with p53 and MDM2 protein expression
22. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers
23. Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinomas
24. An immunohistochemical study of p16, pRb, p21 and p53 proteins in human esophageal cancers
25. Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlated with p53 overexpression in oral squamous cell carcinoma
26. Expression of p16 and lack of pRB in primary small cell lung cancer
27. Cyclin D1 and retinoblastoma susceptibility gene alteration in non-small cell lung cancer
28. Retinoblastoma protein expression in lung cancer: And immunohistochemical analysis
29. Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer
30. INK4A inactivation in non small-cell lung cancers
31. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung
32. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutation in non-small cell lung cancer
33. Significance of p53 and Rb protein expression in surgically treated non-small cell lung cancers
34. INK4 expression in primary lung cancers and cell lines
35. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions
36. The E7 proteins of the non-nic human oncogenic papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties
37. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
38. ARF protein encoded by the β transcript of the p16INK4a gene is frequently lost in small cell lung cancer
39. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer
40. Amplification of a gene encoding a p53-associated protein in human sarcomas
41. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
42. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
43. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma
44. MDM2/p53 co-expression in oral premalignant and malignant lesions: Potential prognostic implications
45. Aberrations of the p53 pathway components p53, MDM2; and CDKN2A appear independent in diffuse large B-cell lymphoma
46. 1-S transition control gene abnormalities
47. ARF
48. Induction of WAF1/CIP1 by a p53-independent pathway
49. Induction of p21 (WAF-1/CIP1) during differentiation
50. DNA methylation and expression of p16 (INK4A) gene in pulmonary adenocarcinoma and anthracosis in background lung
51. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
52. Biological characterization of central and peripheral primary non-small cell lung cancers (NSCLC)
53. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas